Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks

The article describes a first-in-class evaluation of a de-novo drug candidate designed using generative AI for an AI-discovered target, with a focus on aging research. It references AI aging clocks, AI models and assessment of the hallmarks of aging, but provides no clinical efficacy, safety, financial, regulatory or commercialization data. The development milestone is directionally positive for the company’s AI-enabled drug-discovery strategy, though its immediate market impact is likely limited.